Baxter Awaits Further FDA Contact Regarding CAPA, MDR Deficiencies
This article was originally published in The Gray Sheet
Executive SummaryBaxter Healthcare's response to Form 483 inspection observations insufficiently addresses FDA concerns about corrective and preventive actions (CAPA), the agency says in a warning letter released April 19
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.